News ArticleGlobal Health Limited Posts 34% Revenue Growth and 60% EBITDA Increase in Q2 FY2027
The company added 74 new beds and Noida hospital achieved EBITDA breakeven in the quarter ended September 30, 2026
Global Health Limited announced its financial results for Q2 FY2027, reporting a 33.6% year-on-year revenue increase to INR 14,690 million, driven by higher patient volumes and capacity expansion. Operating EBITDA surged 60.2% to INR 3,701 million with improved margins of 25.2%, while PAT rose 38.3% to INR 2,191 million. The company added 74 new beds and achieved EBITDA breakeven at its Noida hospital during the quarter.
Global Health Limited
Investor Presentation
Global Health Limited reported a 33.6% year-on-year increase in revenue to INR 14,690 million for Q2 FY2027, fuelled by rising patient volumes and network expansion. Operating EBITDA rose 60.2% to INR 3,701 million with margin improvement, and PAT increased 38.3% to INR 2,191 million. The company's Noida hospital reached EBITDA breakeven during the quarter.
The company’s inpatient count grew by 29.5% and outpatient count by 37.9% year-on-year. Medanta added 74 beds across the network, with 49 beds in Noida and 25 in Lucknow, increasing total bed capacity to 3,115 compared to 2,658 in the same quarter last year.
Occupied bed days increased 22.4% year-on-year with occupancy at approximately 67%, up from 64% in the previous year’s quarter. Average revenue per patient slightly rose to INR 2.06 lakh, while average length of stay decreased to 2.89 days.
Cluster 1 hospitals (Gurgaon, Indore, Ranchi) saw revenue grow 17.8% year-on-year to INR 8,229 million, with operating EBITDA margin expanding to 22.0%. Cluster 2 hospitals (Lucknow, Patna, Noida) had a 63.2% revenue increase to INR 5,790 million, and operating EBITDA margin rose to 31.7%.
International patient revenue increased 30.3% to INR 993 million, and the OPD pharmacy business grew 52.9% to INR 699 million. The Noida facility reported revenue of INR 1,059 million and achieved an operating EBITDA of INR 86 million, reaching profitability for the first time.
The quarter also saw onboarding of over 100 doctors, addition of advanced medical equipment, and expansion of the pharmacy network to 28 operational outlets across multiple cities.
Highlights
- Q2 FY2027 revenue from operations: INR 14,690 million, up 33.6% year-on-year
- Operating EBITDA: INR 3,701 million, up 60.2%, margin improved to 25.2%
- Profit after tax: INR 2,191 million, 38.3% growth with 14.9% margin
- 74 new beds added in Q2 across network; Noida hospital beds reach 482
- Inpatient volume up 29.5%, outpatient volume up 37.9% year-on-year
- Noida hospital achieves EBITDA breakeven with INR 86 million in operating EBITDA in Q2 FY2027
Key Data Snapshot
What happened
- Global Health Limited reported a 34% year-on-year revenue increase to INR 14,690 million for Q2 FY2027.
- Operating EBITDA rose by 60.2% to INR 3,701 million with a margin improvement to 25.2%.
- Profit after tax increased 38.3% to INR 2,191 million with a margin of 14.9%.
- The company expanded bed capacity by 74 beds across its network in Q2 FY2027.
- Noida hospital generated INR 1,059 million in revenue and achieved operating EBITDA breakeven during the quarter.
Key details
- Patient footfalls increased significantly with inpatient volumes up 29.5% and outpatient volumes up 37.9% year-on-year.
- Medanta's total census bed capacity increased to 3,115 beds in Q2 FY2027 from 2,658 beds in the prior year period.
- Occupied bed days increased 22.4% leading to an occupancy rate of approximately 67%, up from 64% last year.
- Average revenue per patient grew slightly to INR 2.06 lakh while average length of stay reduced to 2.89 days.
- International patient revenue grew 30.3% year-on-year to INR 993 million.
Operational performance
- Cluster 1 hospitals (Gurgaon, Indore, Ranchi) reported INR 8,229 million revenue, growing 17.8% year-on-year with improved EBITDA margins of 22.0%.
- Cluster 2 hospitals (Lucknow, Patna, Noida) showed 63.2% revenue growth to INR 5,790 million and EBITDA margins improved to 31.7%.
- OPD pharmacy business revenue increased by 52.9% to INR 699 million in Q2 FY2027.
- Noida hospital reached operational breakeven with EBITDA of INR 86 million from 482 beds.
Business impact
- Onboarding of over 100 doctors and 65 senior clinicians during Q2 FY2027 strengthened the clinical team across the network.
- Additional operating theatres and advanced medical equipment were deployed to support care delivery.
- Expansion of the pharmacy network to 28 operational sites enhanced continuity of patient care.
- The company’s focus on capacity expansion and patient volume growth supported the improved financial performance.
Highlights
- Q2 FY2027 revenue from operations: INR 14,690 million, up 33.6% year-on-year
- Operating EBITDA: INR 3,701 million, up 60.2%, margin improved to 25.2%
- Profit after tax: INR 2,191 million, 38.3% growth with 14.9% margin
- 74 new beds added in Q2 across network; Noida hospital beds reach 482
- Inpatient volume up 29.5%, outpatient volume up 37.9% year-on-year
- Noida hospital achieves EBITDA breakeven with INR 86 million in operating EBITDA in Q2 FY2027
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on Investor Presentation
View allLatest corporate announcements and market updates in Investor Presentation.
Multi Commodity Exchange of India Ltd Reports Nearly 100% Increase in Total Income for H1 FY27 with ₹1,603 Crore
Multi Commodity Exchange of India Ltd (MCX) reported total income of ₹1,603 crore for the half year ended September 30, 2026, nearly doubling the ₹807 crore recorded in the same period last year. Profit after tax reached ₹868 crore, showcasing substantial financial growth.
Read Full Story
GlaxoSmithKline India Achieves 21% Revenue Growth in Q2 FY27 with Innovation-Driven Portfolio Expansion
GlaxoSmithKline Pharmaceuticals Limited reported a 21% revenue increase to ₹1180 crore in Q2 FY27, driven by strong sales execution and a rising contribution from its innovation portfolio which grew to 7% of total sales. The company sustained market leadership with a 25% share in its representative market amid competitive industry growth.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 mn Revenue in Q2 FY27 with 29% YoY Growth Bolstered by India Formulations
Zydus Lifesciences Limited recorded a 29% year-on-year increase in revenues to Rs. 79,096 million during the second quarter of fiscal year 2027, driven primarily by robust growth in their India branded formulations and North America markets.
Read Full Story
